Medipharm Labs Corp Stock Price To Earnings To Growth
| MEDIF Stock | USD 0.04 0 2.22% |
Medipharm Labs Corp fundamentals help investors to digest information that contributes to Medipharm Labs' financial success or failures. It also enables traders to predict the movement of Medipharm OTC Stock. The fundamental analysis module provides a way to measure Medipharm Labs' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medipharm Labs otc stock.
Medipharm |
Medipharm Labs Corp OTC Stock Price To Earnings To Growth Analysis
Medipharm Labs' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Medipharm Labs Corp has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run My Watchlist Analysis Now
My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
| All Next | Launch Module |
Medipharm Fundamentals
| Return On Equity | -0.57 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (2.07) % | |||
| Operating Margin | (1.61) % | |||
| Current Valuation | 3.05 M | |||
| Shares Outstanding | 280.51 M | |||
| Shares Owned By Insiders | 3.92 % | |||
| Shares Owned By Institutions | 7.05 % | |||
| Price To Book | 0.36 X | |||
| Price To Sales | 0.69 X | |||
| Revenue | 21.71 M | |||
| Gross Profit | (13.42 M) | |||
| EBITDA | (38.55 M) | |||
| Net Income | (54.8 M) | |||
| Cash And Equivalents | 21.99 M | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 1.44 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 5.23 X | |||
| Book Value Per Share | 0.22 X | |||
| Cash Flow From Operations | (13.21 M) | |||
| Earnings Per Share | (0.14) X | |||
| Number Of Employees | 190 | |||
| Beta | 1.15 | |||
| Market Capitalization | 16.26 M | |||
| Total Asset | 92.36 M | |||
| Z Score | 6.6 | |||
| Net Asset | 92.36 M |
About Medipharm Labs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medipharm Labs Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medipharm Labs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medipharm Labs Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Medipharm OTC Stock
Medipharm Labs financial ratios help investors to determine whether Medipharm OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medipharm with respect to the benefits of owning Medipharm Labs security.